True Wealth Design’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

True Wealth Design’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1	Closed	-$108	–	889
2023 Q1	$108	Sell	1 -9	-90%	-$1.04K	﹤0.01%	786
2022 Q4	$1.1K	Buy	+10	New	+$648	﹤0.01%	334

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

True Wealth Design's RXDX Position: Q2 2023 in Review

True Wealth Design sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1 share — an estimated $108 sold.

True Wealth Design first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $1.1K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

True Wealth Design reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
True Wealth Design sold 1 Prometheus Biosciences, Inc. Common Stock share in Q2 2023, an estimated $108.
True Wealth Design first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
True Wealth Design's Prometheus Biosciences, Inc. Common Stock position peaked at $1.1K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on True Wealth Design's 13F filing for Q2 2023, filed 14 Aug 2023.